Monoclonal Antibody Nebokitug Shows Promise for Rare Liver Disease Primary Sclerosing Cholangitis
核心洞察
A multicenter Phase 2 trial led by UC Davis Health (搜索) demonstrated that the monoclonal antibody (搜索) nebokitug was safe and showed potential efficacy in treating primary sclerosing cholangitis (搜索) (PSC (搜索)), a rare liver disease (搜索) with no current effective treatments.
The SPRING trial enrolled 76 patients across five countries and found that nebokitug, which blocks the CCL24 (搜索) protein involved in inflammation and scarring, was well-tolerated with no significant safety concerns.
Patients with more advanced liver scarring showed improvements in key measures including liver stiffness and fibrosis markers compared to placebo, suggesting the treatment may help slow disease progression.
A multicenter Phase 2 trial has demonstrated promising results for nebokitug, a monoclonal antibody (搜索) designed to treat primary sclerosing cholangitis (搜索) (PSC (搜索)), a rare and chronic liver disease (搜索) for which no effective treatments currently exist beyond liver transplantation. The study, led by UC Davis Health (搜索) and published in the American Journal of Gastroenterology, showed that nebokitug was safe and demonstrated potential efficacy in reducing inflammation and fibrosis in PSC patients.
Novel Therapeutic Approach Targets CCL24 Protein
Nebokitug is a laboratory-made antibody engineered to block CCL24 (搜索), a protein that plays a critical role in inflammation and scarring processes within the liver. In PSC (搜索) patients, CCL24 levels are elevated above normal and are found around the bile ducts, where they contribute to progressive liver damage. The therapeutic approach aims to interrupt these harmful processes by targeting both inflammation and fibrosis pathways.
"In the trial, nebokitug demonstrated that it has the potential to change the lives of patients with PSC (搜索) by reducing fibrosis and inflammation, which should lead to improved outcomes," said Christopher Bowlus, chief of Gastroenterology and Hepatology at UC Davis Health (搜索) and one of the lead authors of the publication.
SPRING Trial Design and Patient Population
The Phase 2 SPRING trial enrolled 76 patients across five countries, randomly assigning participants to receive nebokitug at two different doses or placebo through intravenous administration every three weeks for 15 weeks. The primary objective focused on safety assessment, while researchers also measured liver health using blood tests, imaging, and markers associated with liver scarring.
Patients who completed the initial treatment period were eligible to continue nebokitug therapy for up to 48 weeks in an extension phase. Most eligible participants joined the extension portion of the study, indicating strong patient interest in continuing the experimental treatment.
Safety Profile and Efficacy Signals
The trial results demonstrated that nebokitug was safe and well-tolerated among participants, with no significant safety concerns identified during the study period. Importantly, patients with more advanced liver scarring showed improvements in key clinical measures, including liver stiffness and fibrosis markers, compared to those receiving placebo.
"These results suggest this treatment may help slow PSC (搜索) progression by reducing inflammation and scarring, though more research is needed to confirm its long-term benefits," added Bowlus.
Addressing Critical Unmet Medical Need
PSC (搜索) is a rare, chronic liver disease (搜索) characterized by inflammation and scarring of bile ducts that transport bile from the liver to the small intestine for fat digestion. When these ducts become damaged and narrowed, bile accumulates in the liver, leading to progressive liver injury over time. While the exact cause remains unclear, most PSC patients also have inflammatory bowel disease (搜索), suggesting a connection between intestinal inflammation and liver pathology.
Current treatment options focus solely on managing symptoms and complications, with liver transplantation representing the only definitive intervention for advanced cases. The lack of effective therapies creates a significant unmet medical need for the PSC (搜索) patient population.
Path Forward to Regulatory Approval
The encouraging Phase 2 results establish the foundation for a pivotal Phase 3 study designed to further evaluate nebokitug's effectiveness. Successful completion of Phase 3 trials could position the therapy for U.S. Food and Drug Administration approval, potentially providing the first targeted treatment option for PSC (搜索) patients.
"These results are good news for patients with PSC (搜索), who are in desperate need of an effective, FDA-approved therapy," Bowlus emphasized, highlighting the significant clinical impact that an approved PSC treatment could have for this underserved patient population.